Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with ...
Carhart-Harris, who is chair of TYP’s scientific advisory board, and Mediano, of the Imperial College London, will work with Tryptamine Therapeutics’ (ASX:TYP) to develop a proprietary EEG-based ...
The open-label trial will be run in partnership with Swinburne University and plans to test Tryptamine’s IV psilocin therapy TRP-8803, with supportive psychotherapy. Watch the video to hear the ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Tryptamine Therapeutics ( (AU:TYP)) has ...
Tryptamine Therapeutics has entered an exclusive agreement with world-leading psychedelic researchers to develop a first-of-its-kind EEG-based brain entropy biomarker. Carhart-Harris, who is chair of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback